These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9548739)

  • 21. RNA recognition and regulation of HIV-1 gene expression by viral factor Tat.
    Naryshkin NA; Gait MJ; Ivanovskaya MG
    Biochemistry (Mosc); 1998 May; 63(5):489-503. PubMed ID: 9632883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism.
    Wang S; Huber PW; Cui M; Czarnik AW; Mei HY
    Biochemistry; 1998 Apr; 37(16):5549-57. PubMed ID: 9548939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/ TAR RNA binding in HIV-1 transcription.
    Wang W; Guo Z; Chen Y; Liu T; Jiang L
    Chem Biol Drug Des; 2006 Dec; 68(6):314-8. PubMed ID: 17177893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA.
    Rana TM; Jeang KT
    Arch Biochem Biophys; 1999 May; 365(2):175-85. PubMed ID: 10328810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro selection of RNA aptamers that can bind specifically to Tat protein of HIV-1.
    Yamamoto R; Toyoda S; Viljanen P; Machida K; Nishikawa S; Murakami K; Taira K; Kumar PK
    Nucleic Acids Symp Ser; 1995; (34):145-6. PubMed ID: 8841594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescence correlation spectroscopy at single molecule level on the Tat-TAR complex and its inhibitors.
    Nandi CK; Parui PP; Brutschy B; Scheffer U; Göbel M
    Biopolymers; 2008 Jan; 89(1):17-25. PubMed ID: 17764074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides.
    Huq I; Ping YH; Tamilarasu N; Rana TM
    Biochemistry; 1999 Apr; 38(16):5172-7. PubMed ID: 10213623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The interaction of HIV-1 Tat(32-72) with its target RNA: a fluorescence and nuclear magnetic resonance study.
    Metzger AU; Bayer P; Willbold D; Hoffmann S; Frank RW; Goody RS; Rösch P
    Biochem Biophys Res Commun; 1997 Dec; 241(1):31-6. PubMed ID: 9405229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine.
    Lee CW; Cao H; Ichiyama K; Rana TM
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4243-6. PubMed ID: 16054360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
    Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
    Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
    Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies.
    Theisen DM; Pongratz C; Wiegmann K; Rivero F; Krut O; Krönke M
    Vaccine; 2006 Apr; 24(16):3127-36. PubMed ID: 16497417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction.
    Arzumanov A; Walsh AP; Liu X; Rajwanshi VK; Wengel J; Gait MJ
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):471-80. PubMed ID: 11563062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
    He M; Yuan D; Lin W; Pang R; Yu X; Yang M
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3978-81. PubMed ID: 16039124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA.
    Long KS; Crothers DM
    Biochemistry; 1999 Aug; 38(31):10059-69. PubMed ID: 10433713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discoveries of Tat-TAR interaction inhibitors for HIV-1.
    Yang M
    Curr Drug Targets Infect Disord; 2005 Dec; 5(4):433-44. PubMed ID: 16535863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical cross-linking of the human immunodeficiency virus type 1 Tat protein to synthetic models of the RNA recognition sequence TAR containing site-specific trisubstituted pyrophosphate analogues.
    Naryshkin NA; Farrow MA; Ivanovskaya MG; Oretskaya TS; Shabarova ZA; Gait MJ
    Biochemistry; 1997 Mar; 36(12):3496-505. PubMed ID: 9131999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA-protein interactions in the Tat-trans-activation response element complex determined by site-specific photo-cross-linking.
    Wang Z; Rana TM
    Biochemistry; 1998 Mar; 37(12):4235-43. PubMed ID: 9521746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.
    Du Z; Lind KE; James TL
    Chem Biol; 2002 Jun; 9(6):707-12. PubMed ID: 12079782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA.
    Mischiati C; Jeang KT; Feriotto G; Breda L; Borgatti M; Bianchi N; Gambari R
    Antisense Nucleic Acid Drug Dev; 2001 Aug; 11(4):209-17. PubMed ID: 11572598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.